The UK SPIRIT 1 trial in newly diagnosed chronic myeloid leukaemia

Br J Haematol. 2022 Mar;196(6):e55-e57. doi: 10.1111/bjh.17961. Epub 2022 Jan 6.

Authors

Paolo Gallipoli¹, Richard E Clark², Jenny Byrne³, Jane F Apperley⁴, Dragana Milojkovic⁴, Letizia Foroni⁴, John M Goldman⁴, Stephen O'Brien⁵

Affiliations

¹ Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
² Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.
³ Department of Haematology, Nottingham University Hospital Trust, Nottingham, UK.
⁴ Centre for Haematology, Imperial College London at Hammersmith Hospital, London, UK.
⁵ Faculty of Medical Sciences, Newcastle University, Newcastle, UK.

No abstract available

Keywords: chronic myeloid leukaemia; clinical trials; interferon; molecular responses; side-effects; tolerability.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myeloid*
United Kingdom / epidemiology

Substances

Fusion Proteins, bcr-abl

Grants and funding